


Supp Fig 1 : SFRP1 methylation with coculture: DNA methylation analysis shows hypermethylation of selected loci (marked by arrows) in the SFRP1 promoter in the HS27 stromal cells that are co-cultured with KG1a cells.



Supp Fig 2 : Validation of methylation changes with stroma and leukemic cell coculture: DNA methylation analysis shows hypermethylation of selected loci (marked by arrows) in the TNF-alpha promoter in the HS27 stromal cells that are co-cultured with KG1a cells. Hypermethylation was confirmed by Massarray bisulfite epityper analysis (lowerpanel).

MDS22 Isotype 20x




MDS22 UnTx FRZB 20x



MDS22 Aza FRZB 20x




MDS23 Isotype 20x



MDS23 UnTx FRZB 20x





MDS23 Aza FRZB 20x



Supp Fig 3: FRZB upregulation in MDS stroma after 5-Azacytidine treatment: Immunohistochemistry shows increase expression of FRZB in MDS stroma treated with 5-Aza (.5uM) for 5 days.

Supp Fig 4: FRZB knockdown leads to partial inhibition of erythroid differentiation induced by treatment of MDS stroma with 5-Aza : siRNA mediated knockdown of FRZB was achieved in primary MDS stromal cells via siRNAs with scrambled siRNAs as controls. MDS stromal cells were then pretreated with 5-Aza for 5. Co-culture of healthy CD34 cells with MDS stroma was performed for 14 days and FACS analysis done (A,B). 5-Aza pretreatment of MDS stroma led to increase in Glycophorin A positive cells that was partially inhibited with FRZB knockdown (B).



Supp Fig 5: The expression of WNT signature genes in MDS and control marrow derived CD34+ cells is shown in the heatmap. The genes that are significantly differentially expressed in MDS when compared to controls are marked with asterisk. Subtypes of MDS are indicated below

